NCT06472076进行中（未招募）3 期
A Randomized, Multicenter, Double-blind, Phase 3 Study to Investigate the Safety and Efficacy of Belrestotug in Combination With Dostarlimab Compared With Placebo in Combination With Pembrolizumab in Participants With Previously Untreated, Unresectable, Locally Advanced or Metastatic PD-L1 Selected Non-small Cell Lung Cancer (GALAXIES Lung-301)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 88
- 试验地点
- 109
- 主要终点
- Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
研究概览
简要总结
The goal of this clinical trial is to evaluate the safety and tolerability profile of dostarlimab in combination with belrestotug when compared with pembrolizumab and placebo in participants with previously untreated, unresectable, locally advanced or metastatic PD-L1 high NSCLC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Has a histologically or cytologically confirmed diagnosis of locally advanced, unresectable NSCLC (not eligible for curative surgery and/or definitive radiotherapy with or without chemotherapy), or Metastatic NSCLC
- •Has not received prior systemic therapy for their locally advanced or metastatic NSCLC.
- •Provides a fresh tumor tissue sample obtained at the time of or after the initial diagnosis of locally advanced or metastatic NSCLC.
- •Has a PD-L1-high (Tumor cells [TC] ≥50%) tumor
- •Has measurable disease (at least 1 target lesion) based on RECIST 1.1
- •Has an Eastern Cooperative Oncology Group (ECOG) Performance status (PS) score of 0 or
- •Has adequate organ function
排除标准
- •Has NSCLC with a tumor that harbors any of the following molecular alterations:
- •Epidermal growth factor receptor (EGFR) mutations that are sensitive to available targeted inhibitor therapy
- •Anaplastic lymphoma kinase (ALK) translocations that are sensitive to available targeted inhibitor therapy
- •Any other known genomic aberrations or oncogenic driver mutations for which a locally approved targeted therapy is available for first line treatment of locally advanced or metastatic NSCLC.
- •Has had surgery within 4 weeks of the first dose of study intervention and has not recovered from AEs (i.e., has any ongoing surgery-related events ≥ Grade 1)/complications related to surgery or has received lung radiation therapy of >30 gray (Gy) within 6 months
- •Has received prior therapy with any immune checkpoint inhibitors, including antibodies or drugs targeting PD-(L)1, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), T cell immunoglobulin and ITIM domain (TIGIT), or other checkpoint pathways.
- •Has never smoked, defined as smoking <100 tobacco cigarettes in a lifetime.
- •Has an invasive malignancy or history of invasive malignancy other than the disease under study within the last 5 years, with the exception of those with a negligible risk of metastasis or death and/or treated with expected curative outcome.
- •Has symptomatic, untreated, or actively progressin g brain metastases or leptomeningeal disease
- •Has autoimmune disease or syndrome (current or history thereof) that required systemic treatment within the past 2 years.
- •Has received any live vaccine within 30 days prior to first dose of study intervention.
- •Has any history of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis.
- •Has symptomatic ascites, pleural effusion, or pericardial effusion.
- •Has active inflammatory bowel disease
- •Has a history of significant acute or chronic cardiac diagnosis requiring intervention/treatment in the last 6 months.
- •Has severe infection or complication thereof 4 weeks prior to randomisation including active tuberculosis.
- •Has a history of allogeneic tissue/stem cell transplant or solid organ transplant.
研究组 & 干预措施
Pembrolizumab plus placebo
Active Comparator
干预措施: Placebo (Drug)
Dostarlimab plus belrestotug
Experimental
干预措施: Dostarlimab (Biological)
Pembrolizumab plus placebo
Active Comparator
干预措施: Pembrolizumab (Biological)
Dostarlimab plus belrestotug
Experimental
干预措施: Belrestotug (Biological)
结局指标
主要结局
Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
时间窗: Up to approximately 138 weeks
Number of Participants with TEAEs or SAEs leading to dose withdrawals or treatment discontinuation
时间窗: Up to approximately 138 weeks
次要结局
未报告次要终点
研究者
研究点 (109)
Loading locations...
相似试验
招募中
2 期
SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)Endometrial Cancer Stage IMmr DeficiencyEndometrioid Endometrial AdenocarcinomaImmune-related Adverse EventNCT06278857Queensland Centre for Gynaecological Cancer10
进行中（未招募）
3 期
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial CancerNeoplasmsNCT03981796Tesaro, Inc.785
招募中
3 期
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell CarcinomaNeoplasms, Head and NeckNCT06256588GlaxoSmithKline864
招募中
2 期
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSIPancreatic AdenocarcinomaAmpulla of Vater CarcinomaNeuroendocrine CarcinomaSoft Tissue SarcomaSmall Bowel AdenocarcinomaDuodenum AdenocarcinomaGastric AdenocarcinomaAdrenocortical CarcinomaNCT06333314UNICANCER120
进行中（未招募）
2 期
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial CancerCarcinomaNCT06317311GlaxoSmithKline41